PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Enoxaparin - VTE prevention post hip/knee replacement

PAD Profile : Enoxaparin - VTE prevention post hip/knee replacement

Keywords :
VTE prophylaxis, venous thromboembolism, Low molecular weight heparins, LMWH, SWLEOC guidelines
Brand Names Include :
Clexane, Inhixa, enoxaparin BECAT, Arovi

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Prescribe by brand. RSCH / SASH = Inhixa. ASPH = Clexane
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
23 February 2021
East Surrey MOG

East Surrey / SASH local recommendation:

Inhixa is the preferred brand of enoxaparin at Surrey and Sussex Healthcare NHST trust. Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

See Inhixa communication document for GPs below

22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance. Note; differences in the mechanisms for operation in needle guard between presentations of enoxaparin.
29 October 2003
Not Set
The use of LMWH to prevent VTE post operatively is considered as red on the traffic light system. The full course of treatment should be supplied by the Acute Trust.
06 November 2024
NW Surrey Medicines Optimisation Group

North West Surrey / ASPH local recommendation:

Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).

Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.

There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.

See the "NWS Enoxaparin brand switch" document for details

Associated BNF Codes

02. Cardiovascular System
02.08.01. Parenteral anticoagulants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More